{"corpus_id":382332,"paper_sha":"37fda9a29d0b7c4f305557c28fd1350d157bb603","doi":"10.1038/nature09454","arxiv_id":null,"pmid":20823850,"pmcid":"2948082","mag_id":1971947883,"dblp_id":null,"acl_id":null,"title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","year":2010,"publication_date":"2010-09-13","venue":"Nature","journal":{"name":"Nature","pages":"596 - 599","volume":"467"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial, Phase I","Journal Article","Research Support, N.I.H., Extramural"],"s2_fields_of_study":["Biology","Medicine"],"reference_count":29,"citation_count":1758,"influential_citation_count":63,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Alleles","mj":false,"ui":"D000483"},{"d":"Animals","mj":false,"ui":"D000818"},{"d":"Dogs","mj":false,"ui":"D004285"},{"d":"Extracellular Signal-Regulated MAP Kinases","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":false,"ui":"Q000037"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D048049"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Indoles","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D007211"},{"d":"MAP Kinase Signaling System","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D020935"},{"d":"Macaca fascicularis","mj":false,"ui":"D008252"},{"d":"Melanoma","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"enzymology","mj":true,"ui":"Q000201"},{"q":"genetics","mj":false,"ui":"Q000235"},{"q":"pathology","mj":false,"ui":"Q000473"}],"ui":"D008545"},{"d":"Models, Molecular","mj":false,"ui":"D008958"},{"d":"Mutant Proteins","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":false,"ui":"Q000037"},{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"genetics","mj":false,"ui":"Q000235"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D050505"},{"d":"Mutation","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"}],"ui":"D009154"},{"d":"Neoplasm Metastasis","mj":false,"ui":"D009362"},{"d":"Phosphorylation","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D010766"},{"d":"Positron-Emission Tomography","mj":false,"ui":"D049268"},{"d":"Proto-Oncogene Proteins B-raf","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":true,"ui":"Q000037"},{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"genetics","mj":false,"ui":"Q000235"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D048493"},{"d":"Rats","mj":false,"ui":"D051381"},{"d":"Substrate Specificity","mj":false,"ui":"D013379"},{"d":"Sulfonamides","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D013449"},{"d":"Vemurafenib","mj":false,"ui":"D000077484"},{"d":"Xenograft Model Antitumor Assays","mj":false,"ui":"D023041"}],"chemicals":[{"n":"Indoles","ui":"D007211","reg":"0"},{"n":"Mutant Proteins","ui":"D050505","reg":"0"},{"n":"Sulfonamides","ui":"D013449","reg":"0"},{"n":"Vemurafenib","ui":"D000077484","reg":"207SMY3FQT"},{"n":"BRAF protein, human","ui":"C482119","reg":"EC 2.7.11.1"},{"n":"Proto-Oncogene Proteins B-raf","ui":"D048493","reg":"EC 2.7.11.1"},{"n":"Extracellular Signal-Regulated MAP Kinases","ui":"D048049","reg":"EC 2.7.11.24"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumours are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients. Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity. Preclinical experiments demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts. Toxicology studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clinical trials using a crystalline formulation of PLX4032 (ref. 5). In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following two weeks of treatment. This analysis revealed substantial inhibition of ERK phosphorylation, yet clinical evaluation did not show tumour regressions. At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumours of patients correlated with clinical response. Indeed, the Phase 1 clinical data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily. These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.","claims":[{"public_id":"cl_53b1ac86661b64f94b5e4d92d44cc582","status":"active","text":"BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_53b1ac86661b64f94b5e4d92d44cc582"},{"public_id":"cl_4e91cc4245f3e2b6433fa2dff8654c1d","status":"active","text":"Greater than 80% inhibition of ERK phosphorylation in patient tumours correlated with clinical response at higher exposure achieved by the amorphous formulation.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4e91cc4245f3e2b6433fa2dff8654c1d"},{"public_id":"cl_57369bf9715c981603c7e92c98dd4828","status":"active","text":"PLX4032 (RG7204) was discovered as a potent structure-guided inhibitor of oncogenic B-RAF kinase activity.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_57369bf9715c981603c7e92c98dd4828"},{"public_id":"cl_240323614ea33fcda22f7fbd225d1b31","status":"active","text":"PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF-mutant cells and caused regression of BRAF-mutant xenografts in preclinical experiments.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_240323614ea33fcda22f7fbd225d1b31"},{"public_id":"cl_1f017726d1cc5d9e1ff08ac3346f2afd","status":"active","text":"Paired biopsy analysis showed substantial ERK phosphorylation inhibition after two weeks of treatment, but clinical evaluation did not show tumour regressions with the crystalline formulation.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_1f017726d1cc5d9e1ff08ac3346f2afd"},{"public_id":"cl_9425c0e5ac7503be49ee1374bb2b5c7f","status":"active","text":"Phase 1 treatment with 960 mg twice daily produced an 81% response rate in metastatic melanoma patients.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_9425c0e5ac7503be49ee1374bb2b5c7f"}],"concepts":[{"public_id":"co_00ff9a6ecf5bc4d21ea87fbc21c7fe21","status":"active","name":"B-RAF kinase activity","description":"Kinase signaling activity of the B-RAF protein targeted by the inhibitor.","types":["molecular activity"],"aliases":["BRAF kinase activity"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_00ff9a6ecf5bc4d21ea87fbc21c7fe21"},{"public_id":"co_0907c6d54ef74d50ebb81fa9ae41977a","status":"active","name":"BRAF-mutant melanomas","description":"Melanomas harboring activating BRAF mutations.","types":["cancer subtype"],"aliases":["B-RAF mutant melanomas"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0907c6d54ef74d50ebb81fa9ae41977a"},{"public_id":"co_0d28eabfa4ea29871dadd9d23b6848ab","status":"active","name":"PLX4032 (RG7204)","description":"A potent small-molecule inhibitor developed to target oncogenic B-RAF kinase activity.","types":["drug","inhibitor"],"aliases":["PLX4032","RG7204"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0d28eabfa4ea29871dadd9d23b6848ab"},{"public_id":"co_115c35c0e816966a63ddb34b6e24e069","status":"active","name":"amorphous drug formulation","description":"A non-crystalline formulation used to achieve higher drug exposure.","types":["formulation"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_115c35c0e816966a63ddb34b6e24e069"},{"public_id":"co_1639a2d15bb5d5f12f598594d1e547c7","status":"active","name":"ERK phosphorylation","description":"Phosphorylation of ERK used here as a biomarker of pathway inhibition.","types":["biomarker","molecular measurement"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1639a2d15bb5d5f12f598594d1e547c7"},{"public_id":"co_284b5469414bda507e686d9e6fbb22f3","status":"active","name":"BRAF-mutant cells","description":"Cells carrying activating BRAF mutations used in the preclinical experiments.","types":["cell line","experimental model"],"aliases":["B-RAF mutant cells"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_284b5469414bda507e686d9e6fbb22f3"},{"public_id":"co_2af9e26fde5a34c3b32bc4168e7c1c45","status":"active","name":"BRAF-mutant xenografts","description":"Transplanted tumor models derived from BRAF-mutant cells or tumors.","types":["animal model","tumor model"],"aliases":["B-RAF mutant xenografts"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2af9e26fde5a34c3b32bc4168e7c1c45"},{"public_id":"co_2c6d8382337c2e1c0947d934bbd102e6","status":"active","name":"RAF/MEK/ERK pathway","description":"A signaling cascade downstream of RAF that includes MEK and ERK.","types":["signaling pathway"],"aliases":["MAPK pathway"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2c6d8382337c2e1c0947d934bbd102e6"},{"public_id":"co_42d210c91bfc9b586bcd9a7be4c7abff","status":"active","name":"crystalline formulation of PLX4032 (RG7204)","description":"A crystalline drug formulation used in the initial clinical testing of PLX4032.","types":["formulation"],"aliases":["crystalline formulation"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_42d210c91bfc9b586bcd9a7be4c7abff"},{"public_id":"co_5f4fba9beccd635693ef3a561de7c0a8","status":"active","name":"Phase 1 clinical trials","description":"Early-stage human trials used to evaluate safety and preliminary efficacy.","types":["clinical trial phase"],"aliases":["Phase 1"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5f4fba9beccd635693ef3a561de7c0a8"},{"public_id":"co_6e087e9140b73c91094d821c5f725b80","status":"active","name":"structure-guided discovery","description":"A compound discovery approach guided by structural information about the target.","types":["method"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6e087e9140b73c91094d821c5f725b80"},{"public_id":"co_7c29e833dac77dae4574172b850b49db","status":"active","name":"metastatic melanoma patients","description":"Patients with melanoma that had spread beyond the original site.","types":["patient population"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7c29e833dac77dae4574172b850b49db"},{"public_id":"co_8fff0fcc4d5de6b8dc2dd2ee3179057a","status":"active","name":"oncogenic B-RAF kinase activity","description":"Aberrant kinase activity driven by oncogenic BRAF mutations.","types":["molecular activity"],"aliases":["oncogenic B-RAF activity"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8fff0fcc4d5de6b8dc2dd2ee3179057a"},{"public_id":"co_b8f227a68ed135317063f2db4d108128","status":"active","name":"960 mg twice daily","description":"The oral dosing regimen used for the reported metastatic melanoma cohort.","types":["dose"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b8f227a68ed135317063f2db4d108128"},{"public_id":"co_c55405f6ecc86b994b11bbf5bf27200b","status":"active","name":"clinical response","description":"A favorable patient outcome measured by tumor response to treatment.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c55405f6ecc86b994b11bbf5bf27200b"},{"public_id":"co_d82c2d98024c87b0b8a3d9f9f1f97439","status":"active","name":"paired biopsy specimens","description":"Matched tumor biopsy samples collected before and after treatment.","types":["specimen","clinical sample"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d82c2d98024c87b0b8a3d9f9f1f97439"}],"external_ids":{"DOI":"10.1038/nature09454","ArXiv":null,"PubMed":20823850,"PubMedCentral":"2948082","MAG":1971947883,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/382332","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":636451,"paper_uid":"5c5b7515-cad8-4309-87b5-5de59bacfe53","canonical_identity":{"paper_id":636451,"paper_uid":"5c5b7515-cad8-4309-87b5-5de59bacfe53","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/382332"}